// Script to change toggle default state //G Smith second script to show/hide Leadership sections

Patents

NeOnc is the holder of a large portfolio of both domestic and international patents covering its unique and novel drug delivery technology. NeOnc is dedicated to pursuing an aggressive strategy of protecting its IP to ensure its ability to compete in the marketplace.

 

History of Success

Our success is built on over a decade and a half of thorough research and product development focused entirely on advancing our novel delivery methodologies and therapeutic formulations for CNS-based disease. That research is supported by a team of physicians from around the world who each have long and proven track records of success in their fields of endeavor including, oncology, neurology, neurosurgery, clinical research, and drug development.

Patents and Claims

To date, our discoveries have been backed by more than 130 patent applications in the U.S. and internationally; of which 93 have already been issued. In addition, the company has conducted several research studies and clinical trials, all of which have been published and peer-reviewed.

Pending

Issued

U.S.

14

28

International

28

65

TOTAL

42

93

Composition & Method Claims

Issued and Pending Patent Applications*

  • NEO100 Ultrapure POH – Issued patents expiring in 2031: U.S., Canada, UK, EU and China.

  • POH Conjugates such as Temozolomide NEO212 or Rolipram NEO214  – Issued patents expiring in 2031: U.S., UK, EU and Japan.

  • NEO400 POH conjugated to linoleic acid – Anticipated expiration of pending applications expiring in 2031 U.S., EU and China.

  • NEO412 POH conjugates with fatty acid and a compound such as Temozolomide / Rolipram – Issued patents expiring in 2036: U.S., UK, EU, China, Japan and Australia.

  • NEO218 POH conjugated to bromopyruvate

  • NEO216 POH conjugated to Valproic Acid – Anticipated expiration of pending applications expiring in 2038: U.S., EU, and China.

*Note: This does not include all patents

Method of Treatment Claims

Patents  pending applications for indications:

  • Brain Metastases (US. Patent No. 9,913,838)
  • Neurofibromatosis (US. Patent No. 9,913,838)
  • Nasopharyngeal Carcinoma (US. Patent No. 9,987,271)